- The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?Carla Meyer-Massetti
Department of Clinical Pharmacy, School of Pharmacy, University of California San Francisco, Medication Outcomes Center, San Francisco, California, USA
J Hosp Med 5:E8-16. 2010..We reviewed the evidence for the FDA warning and provide a potential medical center response to this warning...
- Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol caseCarla Meyer-Massetti
Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
Int J Clin Pharm 33:806-14. 2011..Intravenous haloperidol is commonly used as a first line treatment for acute delirium. Consequently, the extended warning has caused uncertainty among health care professionals...